Overview

To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
To compare the safety and pharmacokinetic properties between the administration of DWP16001 and DWC202213 as an individual drug, and the administration of DWJ1563 as a combination drug.
Phase:
Phase 1
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.